These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 31695803)

  • 1. Nanoparticle Delivery of Immunostimulatory Agents for Cancer Immunotherapy.
    Zhuang J; Holay M; Park JH; Fang RH; Zhang J; Zhang L
    Theranostics; 2019; 9(25):7826-7848. PubMed ID: 31695803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy.
    Lim S; Park J; Shim MK; Um W; Yoon HY; Ryu JH; Lim DK; Kim K
    Theranostics; 2019; 9(25):7906-7923. PubMed ID: 31695807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery strategies of cancer immunotherapy: recent advances and future perspectives.
    Zhao Z; Zheng L; Chen W; Weng W; Song J; Ji J
    J Hematol Oncol; 2019 Nov; 12(1):126. PubMed ID: 31779642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy.
    Huang P; Wang X; Liang X; Yang J; Zhang C; Kong D; Wang W
    Acta Biomater; 2019 Feb; 85():1-26. PubMed ID: 30579043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular Bioparticulates with Therapeutics for Cancer Immunotherapy.
    Wang C; Wen D; Gu Z
    Bioconjug Chem; 2018 Mar; 29(3):702-708. PubMed ID: 29227626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential applications of nanoparticles in cancer immunotherapy.
    Jia Y; Omri A; Krishnan L; McCluskie MJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):63-74. PubMed ID: 27870598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects.
    Hernández-Gil J; Cobaleda-Siles M; Zabaleta A; Salassa L; Calvo J; Mareque-Rivas JC
    Adv Healthc Mater; 2015 May; 4(7):1034-42. PubMed ID: 25846677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local delivery of checkpoints antibodies.
    Wang C; Ye Y; Gu Z
    Hum Vaccin Immunother; 2017 Jan; 13(1):245-248. PubMed ID: 27668759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
    Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
    J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanotechnology-based products for cancer immunotherapy.
    Shams F; Golchin A; Azari A; Mohammadi Amirabad L; Zarein F; Khosravi A; Ardeshirylajimi A
    Mol Biol Rep; 2022 Feb; 49(2):1389-1412. PubMed ID: 34716502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanotechnology synergized immunoengineering for cancer.
    Chauhan DS; Dhasmana A; Laskar P; Prasad R; Jain NK; Srivastava R; Jaggi M; Chauhan SC; Yallapu MM
    Eur J Pharm Biopharm; 2021 Jun; 163():72-101. PubMed ID: 33774162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
    Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
    Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle mediated cancer immunotherapy.
    Gupta J; Safdari HA; Hoque M
    Semin Cancer Biol; 2021 Feb; 69():307-324. PubMed ID: 32259643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-cytokine fusion proteins.
    Kontermann RE
    Arch Biochem Biophys; 2012 Oct; 526(2):194-205. PubMed ID: 22445675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
    Gerber HP; Sapra P; Loganzo F; May C
    Biochem Pharmacol; 2016 Feb; 102():1-6. PubMed ID: 26686577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles.
    Da Silva CG; Camps MGM; Li TMWY; Zerrillo L; Löwik CW; Ossendorp F; Cruz LJ
    Theranostics; 2019; 9(22):6485-6500. PubMed ID: 31588231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy.
    Mukalel AJ; Riley RS; Zhang R; Mitchell MJ
    Cancer Lett; 2019 Aug; 458():102-112. PubMed ID: 31100411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle delivery systems in cancer vaccines.
    Krishnamachari Y; Geary SM; Lemke CD; Salem AK
    Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering nanoparticle strategies for effective cancer immunotherapy.
    Yoon HY; Selvan ST; Yang Y; Kim MJ; Yi DK; Kwon IC; Kim K
    Biomaterials; 2018 Sep; 178():597-607. PubMed ID: 29576282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticles for tumor immunotherapy.
    Zang X; Zhao X; Hu H; Qiao M; Deng Y; Chen D
    Eur J Pharm Biopharm; 2017 Jun; 115():243-256. PubMed ID: 28323111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.